Cancer diagnostics often begin with a biopsy and histopathologic examination, from the basis of physical examination and medical history. Sometimes the first indication is an abnormal laboratory test result (eg, anemia resulting from colon cancer).
Whole genome and exome sequencing is being widely used to identify disease-causing variants in patients with hereditary and rare diseases. Discovering the true disease-causing variants often...
DATE: October 11, 2016
TIME: 8:00am PT, 11:00 ET
Chronic Renal Dysfunction (CKD) and Acute Kidney Injury (AKI) are increasing in prevalence today and can be escalated due to d...
Precision medicine is a rapidly evolving paradigm powered by emerging technological, diagnostic, and pharmacological capabilities. The clinical application of precision medicine holds p...
Intra-tumor heterogeneity is a major obstacle to cancer treatment. Existing single-cell studies of intra-tumor heterogeneity have largely focused on DNA mutations; functional heterogeneity is...
Circulating Tumor Cells (CTCs) have been extensively explored as circulating biomarkers in various cancers. Due to their rarity, heterogeneity and stem cell-like properties, detecting and pro...
FTIR spectroscopic imaging is an emerging tool for label-free, non-destructive characterization of tissues. The pathological annotation of tissue can be performed in an automated and objectiv...
The talk will first report on a new patented method of counting CTCs based on the metabolism of tumor cells, that favors acidification of their near environment. In order to maintain the acid...
Urinalysis is one the oldest, most established, and most frequently ordered laboratory tests. However, there is wide variation in the methods, processes, quality checks, specifications,...
DATE: August 11, 2016
TIME: 11:00AM PST, 2:00PM ET, 7:00PM GMT
The central dogma that forms the backbone of molecular biology is that DNA codes for RNA (transcription) which then c...
Medicare is clearly moving to a pay for value paradigm, and commercial payers continue their own march away from traditional fee-for-service payment. How can you develop and articulate a pers...
DATE: June 30, 2016
TIME: 8:00am Pacific time, 11:00am Eastern time
Focusing solely on malignant cancer cells and the genes that they express is modestly just a glimpse of the...
I will be discussing the following subjects in my presentation: Update from 2015 PAMA Proposed (or Final Rule) FDA Regulation of LDTs Change to Physician Payment and impact on diagn...
In order to realize the benefits of personalized cancer therapy, increasing demands are placed upon clinical laboratories to provide timely, comprehensive, clinically actionable, and analytic...
Circulating tumor cells (CTCs) is an emerging source used molecular cancer diagnostics. Through expression profiling of CTCs, it allows a deeper understanding about which metabolic pathways e...
The clinical utility of high-dimensional molecular profiling has been provisionally established in several domains of medicine. Today, interrogation of scores of genes and even whole ex...
Self-assembling protein microarrays arrays can be used to study protein-protein interactions, protein-drug interactions, search for enzyme substrates, and as tools to search for disease bioma...
9:00 AM PT, 11:00 AM CT, 12:00 PM ET
Epigenetics defines the set of distinct and heritable molecular mechanisms able to influence gene expression without altering the primary genetic seque...
A recently discovered communication system used by cells to send messages across the human body promises to revolutionize our understanding of disease and how we treat it. Technologies based...
Cervical cancer screening has been the 20th century poster child for preventative screening. This presentation is a gynecologist’s perspective on its continuing evolution –b...
The Personalized Medicine Initiative (PMI) is a non-profit enterprise based in Vancouver, Canada that is focused on introducing personalized, molecularly-based medicine into the front lines o...
Pathology departments are under significant pressure to meet the demands of a precise medicine environment where general phenotypic attributes are no longer sufficient for accurately defining...
Oncologists and pathologists are increasingly utilizing information on genomic alterations in tumors to help guide patient care and treatment. Personalis, Inc., a genomic sequencing and inter...
The advent of personalized medicine employing molecular targeted therapies has markedly changed the treatment of cancer in the past 10 years. Although tumor tissue biopsy-based genotyping is...
Recent advances in next-generation sequencing (NGS) have helped to accelerate the pace of discovery in the field of genetic disease research and testing. The ability to analyze multiple genes...
Whole genome and exome sequencing is being widely used to identify disease-causing variants in patients with hereditary and rare diseases. Discovering the true disease-causing variants often...
DATE: October 11, 2016
TIME: 8:00am PT, 11:00 ET
Chronic Renal Dysfunction (CKD) and Acute Kidney Injury (AKI) are increasing in prevalence today and can be escalated due to d...
Precision medicine is a rapidly evolving paradigm powered by emerging technological, diagnostic, and pharmacological capabilities. The clinical application of precision medicine holds p...
Intra-tumor heterogeneity is a major obstacle to cancer treatment. Existing single-cell studies of intra-tumor heterogeneity have largely focused on DNA mutations; functional heterogeneity is...
Circulating Tumor Cells (CTCs) have been extensively explored as circulating biomarkers in various cancers. Due to their rarity, heterogeneity and stem cell-like properties, detecting and pro...
FTIR spectroscopic imaging is an emerging tool for label-free, non-destructive characterization of tissues. The pathological annotation of tissue can be performed in an automated and objectiv...
The talk will first report on a new patented method of counting CTCs based on the metabolism of tumor cells, that favors acidification of their near environment. In order to maintain the acid...
Urinalysis is one the oldest, most established, and most frequently ordered laboratory tests. However, there is wide variation in the methods, processes, quality checks, specifications,...
DATE: August 11, 2016
TIME: 11:00AM PST, 2:00PM ET, 7:00PM GMT
The central dogma that forms the backbone of molecular biology is that DNA codes for RNA (transcription) which then c...
Medicare is clearly moving to a pay for value paradigm, and commercial payers continue their own march away from traditional fee-for-service payment. How can you develop and articulate a pers...
DATE: June 30, 2016
TIME: 8:00am Pacific time, 11:00am Eastern time
Focusing solely on malignant cancer cells and the genes that they express is modestly just a glimpse of the...
I will be discussing the following subjects in my presentation: Update from 2015 PAMA Proposed (or Final Rule) FDA Regulation of LDTs Change to Physician Payment and impact on diagn...
In order to realize the benefits of personalized cancer therapy, increasing demands are placed upon clinical laboratories to provide timely, comprehensive, clinically actionable, and analytic...
Circulating tumor cells (CTCs) is an emerging source used molecular cancer diagnostics. Through expression profiling of CTCs, it allows a deeper understanding about which metabolic pathways e...
The clinical utility of high-dimensional molecular profiling has been provisionally established in several domains of medicine. Today, interrogation of scores of genes and even whole ex...
Self-assembling protein microarrays arrays can be used to study protein-protein interactions, protein-drug interactions, search for enzyme substrates, and as tools to search for disease bioma...
9:00 AM PT, 11:00 AM CT, 12:00 PM ET
Epigenetics defines the set of distinct and heritable molecular mechanisms able to influence gene expression without altering the primary genetic seque...
A recently discovered communication system used by cells to send messages across the human body promises to revolutionize our understanding of disease and how we treat it. Technologies based...
Cervical cancer screening has been the 20th century poster child for preventative screening. This presentation is a gynecologist’s perspective on its continuing evolution –b...
The Personalized Medicine Initiative (PMI) is a non-profit enterprise based in Vancouver, Canada that is focused on introducing personalized, molecularly-based medicine into the front lines o...
Pathology departments are under significant pressure to meet the demands of a precise medicine environment where general phenotypic attributes are no longer sufficient for accurately defining...
Oncologists and pathologists are increasingly utilizing information on genomic alterations in tumors to help guide patient care and treatment. Personalis, Inc., a genomic sequencing and inter...
The advent of personalized medicine employing molecular targeted therapies has markedly changed the treatment of cancer in the past 10 years. Although tumor tissue biopsy-based genotyping is...
Recent advances in next-generation sequencing (NGS) have helped to accelerate the pace of discovery in the field of genetic disease research and testing. The ability to analyze multiple genes...
Follow
